192 related articles for article (PubMed ID: 28353668)
1. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
5. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
Wick W; Wick A; Weiler M; Weller M
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Odia Y; Iwamoto FM; Moustakas A; Fraum TJ; Salgado CA; Li A; Kreisl TN; Sul J; Butman JA; Fine HA
J Neurooncol; 2016 Mar; 127(1):127-35. PubMed ID: 26643807
[TBL] [Abstract][Full Text] [Related]
7. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
8. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
Miyatake S; Furuse M; Kawabata S; Maruyama T; Kumabe T; Kuroiwa T; Ono K
Neuro Oncol; 2013 Jun; 15(6):650-5. PubMed ID: 23460324
[TBL] [Abstract][Full Text] [Related]
11. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
[TBL] [Abstract][Full Text] [Related]
12. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A
J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
15. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab at recurrence in high-grade glioma.
Salmaggi A; Gaviani P; Botturi A; Lamperti E; Simonetti G; Ferrari D; Silvani A
Neurol Sci; 2011 Nov; 32 Suppl 2():S251-3. PubMed ID: 21987287
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Taillibert S; Vincent LA; Granger B; Marie Y; Carpentier C; Guillevin R; Bellanger A; Mokhtari K; Rousseau A; Psimaras D; Dehais C; Sierra del Rio M; Meng Y; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
Neurology; 2009 May; 72(18):1601-6. PubMed ID: 19414728
[TBL] [Abstract][Full Text] [Related]
18. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]